BIO-PATH HOLDINGS
Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous infusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers and prexigebersen-A, a drug product modification of prexigebersen, is under consideration by the FDA to commence Phase 1 studies in solid tumors.
BIO-PATH HOLDINGS
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
2007-01-01
Address:
Houston, Texas, United States
Country:
United States
Website Url:
http://www.biopathholdings.com
Total Employee:
1+
Status:
Active
Contact:
(832)971-6616
Email Addresses:
[email protected]
Total Funding:
46.12 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon WordPress Google Universal Analytics Wordpress Plugins
Similar Organizations
1200 Pharma
1200 Pharma is a medicinal chemistry technology company that accelerates pre-clinical drug discovery and clinical approval timelines.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Signpath Pharma
Signpath Pharma is a biotechnology company developing therapeutics using curcuminoids extracted from the root of the Curcuma longa plant.
Sonnet BioTherapeutics
Sonnet BioTherapeutics is a biotechnology company for innovating biologic drugs of the single or bispecific mechanism of action.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Official Site Inspections
http://www.biopathholdings.com
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Bio-Path Holdings"
Leadership - BioPath Holdings
In addition to his career activities, Mr. Hickey is a member of the Project Management Institute (PMI) and the Drug Information Association (DIA) the foremost professional organization in …See details»
About Bio-Path - BioPath Holdings
Paving the way for revolutionary treatment of disease Bio-Path is a biotechnology company developing targeted therapies for acute myeloid leukemia (AML), lymphoma, chronic lymphocytic leukemia, gynecological cancer and other …See details»
Bio-Path Holdings, Inc. (BPTH) - Yahoo Finance
See the company profile for Bio-Path Holdings, Inc. (BPTH) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
Bio-Path Holdings - Crunchbase Company Profile
Contact Email [email protected] Phone Number (832)971-6616 Bio-Path is a biotechnology company developing DNAbilize, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered …See details»
Bio-Path Holdings, Inc. (BPTH) Company Profile & Overview
6 days ago Ticker Symbol: BPTH: Exchange: NASDAQ: Fiscal Year: January - December: Reporting Currency: USD: CIK Code: 0001133818: CUSIP Number: 09057N300: ISIN …See details»
Bio-Path Holdings Company Profile - Office Locations ... - Craft
Bio-Path Holdings operates as a clinical and preclinical stage oncology focused antisense drug development company. The Company develops products based on DNAbilize, a drug delivery …See details»
Bio-Path Holdings, Inc. (BPTH) - Yahoo Finance
Find the latest Bio-Path Holdings, Inc. (BPTH) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Bio-Path Holdings - PitchBook
Apr 19, 2017 Publication ID Patent Title Status First Filing Date Technology (CPC) Citations; US-20220133775-A1: P-ethoxy nucleic acids for igf-1r inhibition: PendingSee details»
Investors - BioPath Holdings
Investors Be a part of our success. Bio-Path is developing RNAi nanoparticle drugs for some of the most lethal blood cancers and solid tumors. The company’s anticancer drug candidates …See details»
Bio-Path Holdings Reports First Quarter 2024 Financial Results
May 15, 2024 Marks Progress Across Key Clinical and Corporate Goals Strengthened Balance Sheet with $3.5 Million Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, May …See details»
Bio-Path Holdings, Inc. (BPTH) Stock Price, News, Quote & History ...
Find the latest Bio-Path Holdings, Inc. (BPTH) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Bio-Path Holdings Reports Full Year 2023 Financial Results
Aug 3, 2024 A live audio webcast of the call and the archived webcast will be available in the Media section of the Company’s website at www.biopathholdings.com. About Bio-Path …See details»
Bio-Path Holdings, Inc. Announces Pricing of $2.1 Million Public …
HOUSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq:BPTH) (“Bio-Path” or the “Company”), a biotechnology company leveraging its proprietary DNAbilize® …See details»
Bio-Path Holdings
Upgraded clinical organization and hired new Director of Clinical Program Management ... Mail: [email protected]. Tel: (832) 742 -1369. Web: www.biopathholdings.com. 18. …See details»
Bio-Path Holdings, Inc. (BPTH) - Stock Analysis
Nov 22, 2024 Website https://www.biopathholdings.com. Full Company Profile. Financial Performance. Financial Statements. Analyst Forecast. According to 2 analysts, the average …See details»
Bio-Path Holdings Provides Clinical and Operational Update
Bio-Path Holdings Provides Clinical and Operational Update . Company Expects to Achieve Several Near-Term Clinical Milestones . HOUSTON – March 16, 2023 – Bio-Path Holdings, …See details»
Bio-Path Holdings Successfully Completes First Dose Cohort of …
Dec 14, 2023 BP1002 Offers Unique Opportunity for Venetoclax-Resistant Patients by Utilizing RNAi to Limit Cells’ Ability to Produce Bcl-2 ProteinHOUSTON, Dec. 14, 2023 (GLOBE …See details»
Bio-Path Holdings, Inc. - Cruelty Free Investing
Bio-Path Holdings, Inc. is a clinical stage biotechnology company, which focuses on developing therapeutic products utilizing its proprietary liposomal delivery technology designed to …See details»
Bio-Path Holdings Announces Successful Completion of Higher …
Apr 18, 2024 BP1002 Offers Unique Opportunity for Venetoclax-Resistant AML Patients Utilizing RNAi to Limit AML Cell’s Ability to Produce Cancer Enabling Bcl-2 ProteinHOUSTON, April 18, …See details»